ReviewDermatologic therapy
An evolution in switching therapy for psoriasis patients who fail to meet treatment goals.
Review in Dermatologic therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.JAMA dermatology · 2020Pooled it
- When IL-17 inhibitors fail: Real-life evidence to switch from secukinumab to adalimumab or ustekinumab.Dermatologic therapy · 2019Trial
- Pathogenetic Therapy of Psoriasis by Muramyl Peptide.Frontiers in immunology · 2019Trial
- Switching Patterns of Oral Retinoids to Alternative Medications: An Interrupted Time-Series Analysis of Four European Countries.Drug safety · 2026Article
- Treatment Patterns, Drug Survival, and Effectiveness of Tildrakizumab Among Patients with Prior Interleukin-17 Experience in the PPD CorEvitas Psoriasis Registry.Dermatology and therapy · 2026Article
- The Definition of Psoriasis Severity and Treatment Target of Psoriasis: Korean Expert Consensus Using the Modified Delphi Method.Annals of dermatology · 2026Article
- Biological Therapy for Moderate-to-Severe Psoriasis: A 5-Year Analysis of Patients from Lithuania.Medicina (Kaunas, Lithuania) · 2026Article
- Review
- Features Associated with Therapy Switch Among PPD CorEvitas Psoriasis Registry Patients.Dermatology and therapy · 2026Article
- Strategies for Optimal Use of Biological Therapies in Managing Psoriasis: Focus on Secukinumab.Dermatology and therapy · 2025Article
- The Phenomenon of Anti-Drug Antibodies in Psoriasis: Mechanisms, Clinical Impact, and Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Happiness across the borders-A cross-sectional study among patients with psoriasis and atopic dermatitis in Europe.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- PSO-TARGET: a New Tool to Identify the Therapeutic Expectations of Psoriasis Patients Treated with Biologics.Dermatology and therapy · 2025Article
- The Real-World Burden of Moderate-to-Severe Psoriasis in Patients Under Systemic Treatment from Baltic Countries: Data from the CRYSTAL Observational Study.Medicina (Kaunas, Lithuania) · 2025Observational
- Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics.Archives of dermatological research · 2025Observational
- Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.Dermatology and therapy · 2024Article
- Impact of Disease Burden of Patients with Psoriasis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry.Dermatology and therapy · 2024Article
- Using Automated Machine Learning to Predict Necessary Upcoming Therapy Changes in Patients With Psoriasis Vulgaris and Psoriatic Arthritis and Uncover New Influences on Disease Progression: Retrospective Study.JMIR formative research · 2024Article
- Disease severity, treatment patterns, and quality of life in patients with moderate-to-severe psoriasis routinely managed with systemic treatment: results of the CRYSTAL observational study in Central and Eastern European countries.Frontiers in immunology · 2024Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Switching psoriasis treatment is a common, accepted practice that is used to improve disease management and improve patient outcomes (e.g., when patients are experiencing suboptimal efficacy and/or tolerability with a given therapy). Historically, switching treatment was often performed to limit patients' cumulative exposure to conventional systemic agents (e.g., methotrexate, cyclosporine) with the goal of reducing end-organ toxicity. However, the practice of switching treatments has evolved in recent years with the availability of highly effective and tolerable biologic agents. In current practice, near-complete skin clearance with minimal side effects should be a realistic treatment goal for most patients with moderate-to-severe psoriasis, and consideration for switching therapies has shifted to become more focused on achieving maximum possible skin clearance, enhanced quality of life, and improved patient satisfaction. This review provides a discussion of recent guidance on switching psoriasis therapies, including initial considerations for when switching therapy may be advisable and challenges associated with switching therapy, along with an overview of published clinical studies evaluating outcomes associated with switching therapy. The goal of this review is to empower dermatologists to optimally manage their patients' psoriasis by providing the tools needed to develop rational strategies for switching treatments based on the pharmacologic characteristics of available treatments and each patient's clinical needs and treatment preferences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.